How to improve or maintain the sensitivity of EGFR-TKIs, delays the onset of resistance, and overcomes acquired resistance to EGFR TKIs in NSCLC patients is still an area with unmet high clinical needs. Here, EGFR is linked to non-small cell lung carcinoma.